Cargando…
What Influences the Willingness of Blacks and African Americans to Enroll in Preclinical Alzheimer’s Disease Biomarker Research? A Qualitative Vignette Analysis
BACKGROUND: Alzheimer’s disease (AD) begins with an asymptomatic “preclinical” phase, in which abnormal biomarkers indicate risk for developing cognitive impairment. Research is increasingly focused on validating biomarkers to improve reliable diagnosis and timely clinical treatment of AD. Most prec...
Autores principales: | Ketchum, Fred B., Erickson, Claire M., Chin, Nathaniel A., Gleason, Carey E., Lambrou, Nickolas H., Benton, Susan Flowers, Clark, Lindsay R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198766/ https://www.ncbi.nlm.nih.gov/pubmed/35466937 http://dx.doi.org/10.3233/JAD-215521 |
Ejemplares similares
-
Predictors of Willingness to Enroll in Hypothetical Alzheimer Disease Biomarker Studies that Disclose Personal Results
por: Erickson, Claire M., et al.
Publicado: (2022) -
The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research
por: Ketchum, Fred B., et al.
Publicado: (2023) -
Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society
por: Erickson, Claire M., et al.
Publicado: (2022) -
Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing
por: Ketchum, Fred B., et al.
Publicado: (2022) -
Predictors of positive or negative reactions to learning Alzheimer’s biomarker results
por: Erickson, Claire, et al.
Publicado: (2021)